Published in Cancer Weekly, August 2nd, 2005
"To minimize this risk, many HRT users who have not had a hysterectomy use combined estrogen-progestagen preparations or tibolone. Limited information is available on the incidence of endometrial cancer in users of these therapies."
V. Beral and colleagues, Radcliffe Infirmary, Million Women Study Coordinating Center, Oxford, U.K., sought to rectify this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.